The Potential Risks of Lorazepam in Pancreatic Cancer Treatment

A study conducted by researchers at the Roswell Park Comprehensive Cancer Center has found that the use of lorazepam, a commonly prescribed anti-anxiety medication, stimulates the production of IL6, a pro-inflammatory cytokine, in pancreatic cancer cells. The study also revealed that higher levels of IL6 were associated with poorer survival outcomes in patients with pancreatic cancer. These findings suggest a potential link between lorazepam use, IL6 production, and disease progression in pancreatic cancer, highlighting the need for further research in this area.